Muinmos Wins Global Forex Award 2025 for Best KYC Provider
BILLUND, Denmark, June 10, 2025 /PRNewswire/ — Muinmos has once again been recognised as a leader in client onboarding technology, winning the title of Best KYC Provider in the B2B Global Forex Awards 2025. This marks the third consecutive year that Muinmos has received this prestigious accolade. This category recognises the best-of-breed KYC vendor, providing the most complete and fully automated KYC/AML solution, combating financial crime while also improving the end-client's onboarding experience.
The B2B Global Forex Awards, organised by Holiston Media, shine a light on best-in-class providers across the forex ecosystem, recognising providers that drive innovation, deliver exceptional service, and set new standards in the financial services industry.
This year, over 100 businesses entered the B2B Global Forex Awards, with more than 7,500 votes cast by financial institutions, technology providers, FinTech and RegTech specialists. Muinmos secured the highest number of votes in the Best KYC Provider category, which also included Shufti, Sumsub and MAP FinTech.
Archie Humphries, Director at Holiston Media said, 'Transparency is at the heart of these awards,' he continues. 'Each winner is chosen by industry professionals, making this a true benchmark of peer-recognised excellence.'
Remonda Kirketerp-Møller, Founder and CEO, Muinmos said, 'Winning Best KYC Provider once again is a tremendous honour. It validates the strength of our technology and the trust placed in us by the industry. We are extremely grateful to everyone who voted for us.
'Muinmos is very proud to be setting the benchmark for KYC/KYB excellence globally. As regulatory demands continue to evolve, we remain committed to empowering financial institutions with market-leading, fully automated, seamless onboarding solutions which ensure compliance, enhance the client experience, and provide continuous due diligence throughout the client's lifecycle.'
Muinmos' award-winning KYC solution offers comprehensive global coverage and automation across all types of KYC/KYB/AML checks, including support for clients offering FX, CFDs, cryptocurrencies and stocks. The platform is integrated with multiple data sources and performs real-time monitoring to reflect changes in regulatory requirements, client data, and risk profiles.
Muinmos has won Best KYC Provider at the B2B Global Forex Awards for the last three years, since the category launched in 2023. A full list of B2B Global Forex Award winners 2025 is available here.
About MuinmosMuinmos' advanced client onboarding solutions empower financial institutions to achieve smooth customer experience, enhance organisational efficiency, and ensure regulatory compliance.
Muinmos is a firm believer that compliance can be a catalyst for growth. Its proprietary regulatory engine enables clients to easily acquire new markets, efficiently manage compliance requirements and quickly adapt to regulatory changes.
Through integration into numerous data-sources, a market-unique AI-powered rule engine and groundbreaking holistic architecture, Muinmos' ready-to-use SaaS solution helps firms transform their end-to-end KYC/KYB/AML onboarding and client lifecycle management, and achieve true Straight-Through-Processing (STP).
ISO 27001 certified, GDPR compliant and designed to meet a vast array of regulatory requirements (KYC / KYB / AML / CFT / MiFID / MiCA and similar), Muinmos is trusted by financial institutions worldwide to streamline their onboarding processes, from digital identity verification and screening, to corporate data, CRA, pKYC, cross-border client classification, suitability, appropriateness, and much more – all in one platform. For further information, visit www.muinmos.com or follow Muinmos on LinkedIn
Logo – https://mma.prnewswire.com/media/2706635/Muinmos_logo.jpg
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
40 minutes ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Sumsub Upgrades Case Management Solution with AI Assistant for FinCrime Teams
LONDON, June 10, 2025 /PRNewswire/ — Sumsub, a global verification leader, has announced a major AI-powered update to its Case Management solution—a ready-to-use, cross-functional hub for financial crime investigations designed to streamline fragmented risk operations. Built with direct input from fincrime teams and Sumsub clients, the new release introduces AI-driven tools and intelligent automation to help investigators act on risk in real time. The new Case Management solution provides a unified workspace for cross-functional teams, centralizing identity information, payment histories, risk scores, and internal audit notes in one intelligent interface. One of the key features of this upgrade is Summy, Sumsub's new AI Assistant, which provides case summaries and action recommendations for risk, compliance, and fraud teams. Summy gives investigators the full context of each case—covering user background, transaction history, behavioral insights, and more—while suggesting smart next steps to accelerate decision-making. Case Management is included as a core feature across Sumsub's identity verification, anti-fraud, and AML solutions—fully integrated and ready to deploy without complex adoption procedures. This launch comes as financial crime teams face increasingly complex threats. The global average fraud rate surged by 30% year-over-year—from 2.0% in 2024 to 2.6% in 2025 – driven by deepfakes, fraud-as-a-service, and rapidly evolving typologies. Teams must act faster, smarter, and more collaboratively than ever before. Apart from Summy, AI assistant key features include: Pre-built, customizable workflow templates ('Case Blueprints') that can be set up and used straight away Unified access to applicant data, documents, AML flags, and payments—removes silos and accelerates investigations Custom case views and role-based access control tailors visibility of data and sensitive information, with ability to easily move responsibilities and access around team members Real-time risk updates ensure every decision reflects the latest user behavior and transaction patterns Fraud Network Detection uses AI to uncover hidden connections between suspicious users and real–behaviors 'Fragmentation is one of the biggest threats in modern risk management,' said Andrew Novoselsky, Chief Product Officer at Sumsub. 'With the rise of deepfakes and complex fraud schemes, teams can't afford to work in silos. That's why we built a platform that's not just unified, but smart—where AI like Summy supports every step of the investigation. This is a leap forward in making compliance faster, clearer, and more effective. Tested extensively by Sumsub's Quality Control Team, and built on extensive research into fincrime teams and insights gathered during our Customer Advisory Board meetings, this solution was built to address the most pressing challenges in case management. It makes investigations faster, more transparent, and easier to manage for fraud and risk professionals.' To explore the new Case Management solution, visit: About Sumsub Sumsub is a full-cycle verification platform that secures the whole user journey. With Sumsub's customizable KYC, KYB, Transaction Monitoring, and Fraud Prevention solutions, you can orchestrate your verification process, welcome more customers worldwide, meet compliance requirements, reduce costs, and protect your business. Sumsub has over 4,000 clients across the fintech, crypto, transportation, trading, e-commerce, education, and gaming industries, including Bitpanda, Wirex, Avis, Bybit, Vodafone, Duolingo, Kaizen Gaming, and TransferGo. Sumsub has citations in research published by global institutions such as the United Nations and Statista, as well as ongoing consultancy and engagements with INTERPOL.
Malaysian Reserve
2 hours ago
- Malaysian Reserve
MegazoneCloud Wins 2025 Datadog Partner Network (DPN) Partner of the Year
SEOUL, South Korea, June 10, 2025 /PRNewswire/ — MegazoneCloud, a leading AI and cloud technology company has been recognized as the 2025 Datadog Partner Network (DPN) Partner of the Year for APAC by the monitoring and security platform for cloud applications Datadog, Inc. (NASDAQ: DDOG). The announcement comes ahead of the 8th annual DASH conference, hosted by Datadog in New York City. The DPN award winners were chosen based on a comprehensive set of criteria, including revenue growth, delivery capabilities across products and services, and overall contribution to customer success. Over the past year, MegazoneCloud has nearly doubled its Datadog-related revenue and expanded its dedicated technical team to more than 20 professionals. The company has also strengthened its capabilities across sales, engineering, technical support, marketing, and cost optimization—playing a key role in Datadog's growth in the Asia-Pacific region. Datadog recognized MegazoneCloud for its sustained business momentum and strong collaboration with customers, naming it the top-performing partner in APAC for 2025. 'We are pleased to recognize MegazoneCloud as our DPN Partner of the Year for APJ,' said Jarrod Buckley, Vice President, Channels & Alliances at Datadog. 'MegazoneCloud has made significant investments in their Datadog practices, consistently delivered successful outcomes for our joint customers, and achieved outstanding business results.' Inchul Hwang, Chief Revenue Officer at MegazoneCloud, added, 'We're honored to be recognized for the outcomes of our ongoing technical collaboration with Datadog, which has helped enterprises in Korea and globally enhance their monitoring and security capabilities in cloud environments. Moving forward, we'll continue to actively support our customers by breaking down silos and fostering a collaborative culture that drives the broad adoption of AI and cloud technologies—powered by Datadog's unified observability platform.' About MegazoneCloud MegazoneCloud is a leading AI and cloud-native company, home to over 2,000 cloud and AI technology experts. As a trusted digital transformation (DX) partner to more than 7,000 clients worldwide, MegazoneCloud empowers innovation and growth through strategic alliances with major global and domestic cloud service providers (CSPs). The company also collaborates with over 140 independent software vendors (ISVs) and offers a suite of proprietary cloud, AI, and security solutions. Under its vision of 'Transform Tomorrow, Together', MegazoneCloud is committed to building future-ready competitiveness for its customers—powered by cutting-edge technology, data, and the passion of its people. With local operations in nine countries, including Korea, North America, Japan, Southeast Asia, and Oceania, the company continues to grow alongside its global partners and clients. To learn more, visit: .
